Virus del Papiloma Humano (VPH), cáncer y la vacuna contra el VPH – Preguntas frecuentes

+ -Text Size

TEMAS

Referencias

Anhang R, Goodman A, Goldie, SJ. HPV Communication: Review of existing research and recommendations for patient education. CA Cancer J Clin. 2004;54:245-247.

Beibei L, Viscidi RP, Lee JH, et al. Human Papillomavirus (HPV) 6, 11, 16, and 18 Seroprevalence Is Associated with Sexual Practice and Age: Results from the Multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev. 2011;20:990-1002.

Centers for Disease Control and Prevention. Frequently Asked Questions about HPV Vaccine Safety. Accessed at www.cdc.gov/vaccinesafety/Vaccines/HPV/hpv_faqs.html on March 6,2012.

Centers for Disease Control and Prevention. Genital HPV infection - Fact Sheet. Accessed at www.cdc.gov/std/HPV/STDFact-HPV.htm on February 17, 2012.

Centers for Disease Control and Prevention. HPV and Cancer. Accessed at www.cdc.gov/HPV/cancer.html on February 17, 2012.

Centers for Disease Control and Prevention. Human Papillomavirus (HPV). Accessed at www.cdc.gov/HPV/index.html on March 6, 2012.

Centers for Disease Control and Prevention. Reports of Health Concerns Following HPV Vaccination. Accessed at www.cdc.gov/vaccinesafety/Vaccines/HPV/gardasil.html on March 6, 2012.

Centers for Disease Control and Prevention. Who Should NOT Get Vaccinated with these Vaccines? Accessed at www.cdc.gov/vaccines/vpd-vac/should-not-vacc.htm#hpv on March 6, 2012.

Gavin L, MacKay AP, Brown K, et al; Centers for Disease Control and Prevention (CDC). Sexual and reproductive health of persons aged 10-24 years - United States, 2002-2007. MMWR Surveill Summ. 2009;58(6):1-58.

Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377:932-40.

Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital HPV among females in the United States, the National Health and Nutrition Examination Survey, 2003–2006. J Infect Dis. 2011;204(4):566-73.

Kaplan JE, Benson C, Holmes KH, et al; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):71.

Markowitz LE, Dunne EF, Saraiiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 2007;56:1-23.

Moscicki AB, Hills NK, Shiboski S, et al. Risk factors for abnormal anal cytology in young heterosexual women. Cancer Epidemiol Biomarkers Prev. 1999;8:173-178.

Muñoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949-57.

National Cancer Institute. Human Papillomaviruses and Cancer. Accessed at www.cancer.gov/cancertopics/factsheet/Risk/HPV on February 17, 2012.

Nyitray A. Anal cancer and human papillomaviruses in heterosexual men. Curr Oncol. 2008;15:204-205.

Saslow D, Castle P, Cox T, et al. American Cancer Society guidelines for human papillomavirus vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28.

Saslow D, Solomon D, Lawson HW, et al; American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer [published online ahead of print March 14, 2012]. CA Cancer J Clin. 2012;62(3). doi:10.3322/caac.21139.

Slade BA, Leidel L, Vellozi C, et al. Postlicensure safety surveillance for quadravalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750-757.

US Food and Drug Administration. Vaccines, Blood & Biologics. Approved Products: Cervarix. Accessed at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186957.htm on March 6,2012.

US Food and Drug Administration. Vaccines, Blood & Biologics. Approved Products: Gardasil. Accessed at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm on March 6, 2012.

Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645-2654.


Fecha de última actualización: 04/19/2012
Fecha de último cambio o revisión: 04/19/2012